Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  F2 Bioscience VI L.P.
 2. Date of Event Requiring Statement (Month/Day/Year)
06/11/2014		 3. Issuer Name and Ticker or Trading Symbol
Radius Health, Inc. [RDUS]
(Last)
(First)
(Middle)
PO BOX 309, UGLAND HOUSE, SOUTH CHURCH STREET		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

GEORGE TOWN, E9 KY1-1104		 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 587,500
D (1)
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
F2 Bioscience VI L.P.
PO BOX 309, UGLAND HOUSE
SOUTH CHURCH STREET
GEORGE TOWN, E9 KY1-1104		     X    
F2 Capital Ltd
3RD FLOOR, GENEVE PLACE, WATERFRONT DR
PO BOX 3175, ROAD TOWN
TORTOLA, D8 		     X    
Priestley Katherine
SUITE 6, ALBION RIVERSIDE BUILDING
8 HESTER ROAD
LONDON, X0 SW11 4AX		     X    
Globeways Holdings Ltd
3RD FLOOR, GENEVE PLACE, WATERFRONT DR
PO BOX 3175, ROAD TOWN
TORTOLA, D8 		     X    
F2 Bioscience IV GP Ltd.
PO BOX 309, UGLAND HOUSE
SOUTH CHURCH STREET
GEORGE TOWN, E9 KY1-1104		     X    

Signatures

/s/ Morag Law, attorney-in-fact for F2 Bioscience VI, L.P. 06/12/2014
**Signature of Reporting Person Date
/s/ Morag Law, attorney-in-fact for F2 Bioscience IV GP Ltd. 06/12/2014
**Signature of Reporting Person Date
/s/ Morag Law, attorney-in-fact for F2 Capital Ltd. 06/12/2014
**Signature of Reporting Person Date
/s/ Morag Law, attorney-in-fact for Katherine Priestley 06/12/2014
**Signature of Reporting Person Date
/s/ Morag Law, attorney-in-fact for Globeways Holdings Ltd. 06/12/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The reported securities are owned directly by F2 Bioscience VI L.P. ("F2 Science"). F2 Bioscience IV GP Ltd. ("F2 IV GP") is the General Partner of F2 Science. Katherine Priestley and Globeways Holdings Limited are members of F2 IV GP. F2 Capital Limited is an investment adviser to F2 Science. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.